WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest white paper entitled “Beyond Vaccines – How Monoclonal Antibodies Can Help in the Fight Against the COVID-19 Pandemic.” The paper finds that while there are still unknowns about monoclonal antibodies, such as real-life efficacy and long-term effects, they have the potential to effectively target several stages of the COVID-19 disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the world’s overburdened health systems).
The white paper finds that if their role is proven in time, there will be a high demand for monoclonal antibodies, and there is a clear opportunity for pharma companies to develop new antibodies.
“While slow in their uptake, the US distribution of monoclonal antibodies for COVID-19 has started and several companies are developing new antibodies,” said Alexander Fink, Managing Partner, Europe, Trinity Life Sciences. “Vaccines are still the focus; however, it is increasingly clear that vaccines alone are not enough. All in all, there is a place for antibodies in the fight against COVID-19.”
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic commercialization partner, providing evidence-based solutions for the life sciences. With 25 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
